Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

22.14 +0.10 (+0.45%)
Official Closing Price Updated: 7:00 PM EDT, Apr 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
99 100 Next >
3 Stocks Seeing Insider Buys: CNC, PFE, BMY
Investors closely monitor insider buys, as they can give hints surrounding the long-term picture. Let’s take a closer look at the transactions for those interested in trading like the insiders. 
Via Talk Markets
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Biotech Stocks Are Rallying: What Is Your Playbook?
If you have been reading our posts you know that some of the big biotech winners have taken a hit after earnings : LLY, MRK and REGN. But ABBV, GILD, LLY, and VRTX remain among the top performers. 
Via Talk Markets
3 Spectacular High-Yield Dividend Stocks to Buy in November
High yields aren't a warning indicator with these three stocks. 
Via The Motley Fool
2 Magnificent S&P 500 Dividend Stocks Down Year to Date to Buy and Hold Forever
More than a few companies that did well in the past are out of favor with investors. And that could spell opportunity. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Peering Into Pfizer's Recent Short Interest
Via Benzinga
GSK Stock Crumbles As Vaccine Sales Plummet And Miss Expectations
The company said revenue from RSV vaccine tumbled 72%. 
Via Investor's Business Daily
Moderna's Q3 Earnings Beat Overshadowed By Vaccine Demand Slowdown And Market Share Concerns, Analysts Warn
Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker vaccine demand and concerns over upcoming COVID and RSV sales. 
Via Benzinga
Topics Earnings
Exposures COVID-19 Financial
Trump's Potential 'Health Czar' Robert F. Kennedy Jr. Rattles Vaccine Stocks: 'Shoot First Reaction'
Donald Trump has said he will give Robert F. Kennedy Jr. a senior role in his incoming administration to advance his "Make America Healthy Again" agenda. 
Via Benzinga
Topics Government
Exposures Political
2 Healthcare Dividend Stocks That Are Screaming Buys in November
One stock yields 6% today. Another has grown its dividend by 460% over the past decade. Both are blue chip bargains to buy right now. 
Via The Motley Fool
3 Reasons Pfizer Looks Like a No-Brainer Buy Right Now
Pfizer is trading above its 52-week low but is still a dirt cheap buy. 
Via The Motley Fool
Moderna Posts A Surprise Profit As Sales Wallop Views. But Will RSV Be Its Undoing?
The company reported just $10 million in sales of its RSV vaccine, mResvia, widely missing expectations. 
Via Investor's Business Daily
Trump Has Asked Me To Do 3 Things, Says Robert Kennedy Jr.
Robert Kennedy Jr. revealed Trump's directive to tackle health agency corruption, promote science, and end chronic disease. 
Via Benzinga
Topics Government
Exposures Political
2 Magnificent Stocks to Buy That Are Near 52-Week Lows
These stocks near 52-week lows could be ready to rebound. 
Via The Motley Fool
How this award-winning TV host is setting the stage to help protect her health
(BPT) - Award-winning TV host, comedian, actress and author Sherri Shepherd is at increased risk for pneumococcal pneumonia and invasive pneumococcal disease (IPD) because she has diabetes. She doesn't... 
Via Brandpoint
1 Green Flag That's Also a Red Flag for Pfizer Stock
An activist investor has correctly identified a dysfunctional area of the business. 
Via The Motley Fool
Volatility Hits Large Cap Biopharma: Active Rebalancing May Be Required
A bit of earnings and election jitters roiled the market last week reordering the leaderboard in biopharma stocks. 
Via Talk Markets
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
Is Pfizer Stock a Bargain for Long-Term Investors?
Wall Street's bearish take on this proven innovator may not be warranted. 
Via The Motley Fool
2 Sensational Growth Stocks to Buy at a Discount
These growth stocks are looking especially attractive right now. 
Via The Motley Fool
This Beaten-Down Stock Just Gave Investors More Good News: Is it a Buy?
Slowly but surely, the company's prospects are looking more attractive. 
Via The Motley Fool
3 Potential Catalysts That Could Lift Pfizer Stock Before 2025
The pipeline could yield a winner, but so could a few organizational changes. 
Via The Motley Fool
Stock Market Retreats Before Election Day; Microsoft, Apple, Amazon, Google, Meta In Focus: Weekly Review
The major indexes declined, but haven't fallen apart. 
Via Investor's Business Daily
3 Reasons Relying on Social Security Alone Could be a Risk. And 3 Stocks to Invest in Today.
Social Security is likely to deliver less income than you expect. But you can make up the difference and more via dividend-paying stocks. 
Via The Motley Fool
Cancer-Focused ESSA Pharma Ends Prostate Cancer Trial Due to Insufficient Efficacy From Combination Therapy
ESSA Pharma terminates its Phase 2 masofaniten trial in prostate cancer after interim data shows no added efficacy over enzalutamide alone, shifting focus to other priorities. 
Via Benzinga
Stocks Going Ex Dividend In November 2024
The following is a short list of some of the many stocks going ex-dividend during the next month. 
Via Talk Markets
AWKO Files Lawsuit on Behalf of Sickle Cell Patient Against Pfizer’s Subsidiary
San Francisco, California - Trebor Hardiman, a sickle cell patient from California, has filed a lawsuit against Pfizer’s wholly owned subsidiary Global Blood 
Via Law Firm Newswire
Topics Lawsuit
Exposures Financial Legal
3 Factors That Make Pfizer's Ultra-High-Yield Dividend Safer Than You Might Think
Pfizer's dividends should keep flowing and growing. 
Via The Motley Fool
Amgen 'Laser-Focused' On Its Weight-Loss Shot As New Rival Pfizer Follows, Says CFO
The company expects to have topline results from a Phase 2 study later this year. 
Via Investor's Business Daily
Nasdaq Hits Record High Ahead Of Big Tech Earnings: Fear Index Remains In 'Greed' Zone
Via Benzinga
< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.